|
Metabolic syndrome
|
|
Rahmani et al. 2016 [23]
|
Iran
|
RCT double-blind
|
8 weeks
|
Patients with symptoms of MetS (NCEP-ATP III) and diagnosis of NAFLD
|
Case
|
Amorphous dispersion Curcumin (amorphous dispersion preparation, equivalent to 70 mg/d curcuminoids)
|
37
|
46.37 ± 11.57
|
19
|
|
Control
|
Placebo
|
40
|
48.95 ± 9.78
|
19
|
|
Amin et al. 2015 [26]
|
Pakistan
|
RCT double-blind
|
8 weeks
|
Patients with ≥ 3 features of MetS, prediabetes, dyslipidemia and prehypertension
|
Case
|
Turmeric powder 2.4 g/d
|
63
|
42.40 ± 13.70
|
NA
|
|
Control
|
Placebo
|
63
|
41.57 ± 12.80
|
NA
|
|
Yang et al. 2014 [27]
|
Taiwan
|
RCT double-blind
|
12 weeks
|
Patients with diagnosis of MetS (NCEP-ATP III)
|
Case
|
Turmeric extract (equivalent to 1890 mg/d curcuminods)
|
30
|
59.03 ± 10.10
|
12
|
|
Control
|
Placebo
|
29
|
59.61 ± 14.09
|
17
|
|
Type 2 diabetes mellitus
|
|
Rahimi et al. 2016 [24]
|
Iran
|
RCT double-blind
|
3 months
|
Type 2 Diabetic patients
|
Case
|
Curcumin (nano-micelle 80 mg/day)
|
35
|
56.34 ± 11.17
|
17
|
|
Control
|
placebo
|
35
|
60.95 ± 10.77
|
14
|
|
Selvi et al. 2015 [25]
|
India
|
RCT
|
4 weeks
|
Type 2 diabetic patients
|
Case
|
Turmeric powder 2 g/day +Metformin
|
30
|
47.00 ± 7.17
|
30
|
|
Control
|
Metformin (1 g/day)
|
30
|
46.80 ± 6.10
|
30
|
|
Chuengsamarn et al. 2014 [28]
|
Thailand
|
RCT double-blind
|
6 months
|
Type 2 diabetic patients
|
Case
|
Turmeric extract (equivalent to 1500 mg/d curcuminods)
|
107
|
59.16 ± 11.04
|
50
|
|
Control
|
Placebo
|
106
|
59.58 ± 10.71
|
47
|
|
Usharani et al. 2008 [15]
|
India
|
RCT
|
8 weeks
|
Type 2 diabetic patients
|
Case
|
Turmeric extract (equivalent to 600 mg/day curcuminoids)
|
23
|
55.52 ± 10.76
|
12
|
|
Control
|
Placebo
|
21
|
49.75 ± 8.18
|
11
|
